Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration.
about
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.Perispinal etanercept: potential as an Alzheimer therapeuticPerispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanismThe dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γAlzheimer's Disease: Exploring the Role of Inflammation and Implications for TreatmentA Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in DiseaseExcess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsLW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice.Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging.Shiga toxin 1-induced inflammatory response in lipopolysaccharide-sensitized astrocytes is mediated by endogenous tumor necrosis factor alpha.Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model.Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidenceIncreased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's diseaseThe role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease.Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascadesElimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus.The inflammatory response in Alzheimer's disease.Therapeutic Effects of TianDiJingWan on the Aβ 25-35-Induced Alzheimer's Disease Model RatsRole of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone.Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's diseaseEffects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge.Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trialThe Fox and the Rabbits-Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex Reactivation and Other Causes of Alzheimer's DiseaseNeuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease.TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation.Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's diseaseTumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's diseaseTargeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.Cognitive dysfunction with aging and the role of inflammation6-Mercaptopurine attenuates tumor necrosis factor-α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulationEtanercept attenuates traumatic brain injury in rats by reducing brain TNF- α contents and by stimulating newly formed neurogenesisAlzheimer's disease: new diagnostic and therapeutic toolsCell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membraneIs TNF a link between aging-related reproductive endocrine dyscrasia and Alzheimer's disease?Inflammation and aging: can endocannabinoids help?The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments.Role of PPARs in Radiation-Induced Brain Injury.Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
P2860
Q21261380-58D289A5-BE0D-44A4-93D8-C48408CA19DFQ22241758-F4DE665B-3ADE-4805-A1C9-B7BC9A97BDEBQ24652684-8D5727FB-1862-4892-B3C7-2E4F118C94FCQ26750987-9FCBF966-ECCD-46C4-A5BC-2DE4B1FB5A61Q26776157-459FAEF8-9837-4446-AE3E-FEDAFF137497Q26801912-12CF86C6-73D8-47D3-B93D-7277CDE29E17Q28075692-11175267-3586-4B0F-87F0-5E746C1FE2CFQ30831806-A80A2D72-E4FD-4DBD-A291-40F33E8470CBQ33417987-3E70CFC3-7402-4DAC-8B2F-8999741D0171Q33675845-9671115B-E759-440F-8B19-1DA0F7088540Q33810933-7A037E2A-7436-48F9-B3B5-8F0C215701E8Q33856674-174C671D-1ABE-4939-8764-41957D229D9BQ33947639-BB1A45CD-5BEC-47F7-8319-DDF003B63D44Q34129473-0C0B9F77-6F38-4A17-84C4-1FCF4D01CB6CQ34330121-2E373037-582E-4FA3-8E94-48424C400C56Q34499838-9B390381-1FBA-48F7-A436-A0130BBC4D8FQ34671403-7661A700-2324-463D-81B4-212211CD060CQ34803247-53708697-A066-49C0-B860-2724C05CD1D5Q35169744-955682EF-C6D3-40A9-94ED-57EA3093C349Q35287240-5CA5282C-7C05-4977-9CF7-2707EB148236Q35505131-B2812E7B-4C65-4541-81C2-940639DDFDB9Q35647379-45D29287-B22A-4A38-B6F3-D37E7EABB5E4Q35671005-ACAF9EC8-13E0-41B1-85F3-697C40D58FF4Q35687324-A947A391-9393-4114-9022-2DB6F0E6413BQ35791628-D73EB320-4BCD-435C-8A84-81908CCFE4B8Q35818467-8B45D46B-D6D9-40B3-AB82-C7A38E3F23D1Q36071481-4AFAD9B7-80C2-49F7-B5B4-09BE318ABDDFQ36112435-73E4A9E0-DD67-458E-A1A1-2C192AB86DF5Q36118204-F36D5961-6B24-4175-AEED-01641D7D8B25Q36330960-2923DC37-B9CF-4B80-9F1C-F5134BB0C919Q36443732-C1E5C89B-E3DC-4858-B1F1-72C5886F35DBQ36796853-9ED30267-D0D1-4DA5-889B-2F6D7DDAD43AQ36844981-F68E2B7F-456C-4031-96DC-3B09DD72C88CQ36865357-3EC1AFA9-C05C-40CA-9882-CB17CED2A5E9Q37006491-2B4D7FCB-090D-4910-869E-502EDBB96F13Q37120749-F15BF3A8-24D0-4FF2-846E-4165A7203D9DQ37133525-1473F2C9-C987-4803-BE5F-891759E7B112Q37334202-D77CF308-73A0-419D-A0E3-17FD4A31F01DQ37356420-A764B9E4-A4D2-4248-A70B-0B68F898F6CAQ37416147-040E522A-3188-47D2-864B-17F880AEDFAC
P2860
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rapid cognitive improvement in ...... nal etanercept administration.
@ast
Rapid cognitive improvement in ...... nal etanercept administration.
@en
type
label
Rapid cognitive improvement in ...... nal etanercept administration.
@ast
Rapid cognitive improvement in ...... nal etanercept administration.
@en
prefLabel
Rapid cognitive improvement in ...... nal etanercept administration.
@ast
Rapid cognitive improvement in ...... nal etanercept administration.
@en
P2860
P356
P1476
Rapid cognitive improvement in ...... nal etanercept administration.
@en
P2093
Edward L Tobinick
Hyman Gross
P2860
P2888
P356
10.1186/1742-2094-5-2
P577
2008-01-09T00:00:00Z
P5875
P6179
1047779634